News

IntelGenx has announced the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The

The US House of Representatives, and the Society of Chemical Manufacturers and Affiliates (SOCMA) have urged Congress to avoid sweeping changes to the Toxic Substances Control Act (TSCA)

Purdue Pharma and Napp Pharmaceutical have filed a patent infringement petition against Sun Pharmaceuticals and its US subsidiary. The litigation was filed following a para IV certification filed

Aterovax has announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD)

Novartis has reported new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US

Abbott has announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent

“At Loyola, we determined four years ago that the rapid tests for influenza detected only 50 percent of the patients who were positive,” said Paul Schreckenberger, Ph.D., director

Callidus Software has signed a leading pharmaceutical company as a new customer for its on-demand Monaco suite. Under the agreement, signed in the fourth quarter of 2009, the

Genentech has submitted two supplemental Biologics License Applications (sBLAs) to the FDA for Avastin (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic)